Atıl BİSGİN, Funda SARI, Saadet GÜMÜŞLÜ, Ramazan ÇETİNKAYA, Gizem Esra GENÇ, Metin SARIKAYA, Arzu Didem YALÇIN

Autosomal Dominant Polycystic Disease is Associated with Depressed Levels of Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand

Background: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by multiple, large renal cysts and impaired kidney function. Although the reason for the development of kidney cysts is un-known, ADPKD is associated with cell cycle arrest and abundant apoptosis of renal tubular epithelial cells. Aims: We asked whether serum-soluble TNF-related apop-tosis-inducing ligand (sTRAIL) might underlie ADPKD.Study Design: Case-control study. Methods: Serum sTRAIL levels were measured in 44 patients with ADPKD and 18 healthy volunteers. The human soluble TRAIL/Apo2L ELISA kit was used for the in vitro quantitative determination of sTRAIL in serum samples.Results: Mean serum sTRAIL levels were lower in patients with ADPKD as compared to the con-trol group (446.9±103.1 and 875.9±349.6 pg/mL, p0.05). Conclusion: Our results show that ADPKD patients have depressed sTRAIL levels, indicating apoptosis unrelated to the stage of chronic renal failure

PDF

___

Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993;329:332-42. [CrossRef]
Gattone VH 2nd, Calvet JP, Cowley BD Jr, Evan AP, Shaver TS, Helmstader K, et al. Autosomal recessive polycystic kidney disease in a murine model. A gross and microscopic description. Lab Invest 1988;59:231-8.
Zhou XJ, Kukes G. Pathogenesis of autosomal dominant polyc- ystic kidney disease: role of apoptosis. Diagn Mol Pathol 1998;7:65-8. [CrossRef]
Lanoix J, D'Agati V, Szabolcs M, Trudel M. Dysregulation of cellular proliferation and apoptosis mediates human autoso- mal dominant polycystic kidney disease (ADPKD). Oncogene 1996;13:1153-60.
Woo D. Apoptosis and loss of renal tissue in polycystic kidney diseases. N Engl J Med 1995;333:18-25. [CrossRef]
Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673- 82. [CrossRef]
Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ash- kenazi A. Induction of apoptosis by Apo-2 ligand, a new mem- ber of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90. [CrossRef]
Corallini F, Rimondi E, Secchiero P. TRAIL and osteopro- tegerin: a role in endothelial physiopathology? Front Biosci 2008;13:135-47. [CrossRef]
Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-3. [CrossRef]
Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating re- ceptor for TRAIL. EMBO J 1997;16:5386-97. [CrossRef]
Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antago- nist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-8. [CrossRef]
Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21. [CrossRef]
Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF- kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813-20. [CrossRef]
Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing li- gand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003;63:912-6.
Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H. Nature's TRAIL-on a path to cancer immunothe- rapy. Immunity 2003;18:1-6. [CrossRef]
Liabeuf S, Barreto DV, Barreto FC, Chasseraud M, Brazier M, Choukroun G, et al. The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients. Nephrol Dial Transplant 2010;25:2596-602. [CrossRef]
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al A New Equation to Estimate Glomerular Filt- ration Rate. Ann Intern Med 2009;150:604-12. [CrossRef]
K/DOQI clinical practice guidelines for chronic kidney disea- se: evaluation, classification, and stratification. National Kidney Foundation. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.
Murcia NS, Sweeney WE Jr, Avner ED. New insights into the molecular pathophysiology of polycystic kidney disease. Kidney Int 1999;55:1187-97. [CrossRef]
Trudel M, Barisoni L, Lanoix J, D'Agati V. Polycystic kidney disease in SBM transgenic mice: role of c-myc in disease induc- tion and progression. Am J Pathol 1998;152:219-29.
Winyard PJ, Nauta J, Lirenman DS, Hardman P, Sams VR, Ris- don RA, et al. Deregulation of cell survival in cystic and dysplas- tic renal development. Kidney Int 1996;49:135-46. [CrossRef]
Ecder T, Melnikov VY, Stanley M, Korular D, Lucia MS, Schrier RW, et al. Caspases, Bcl-2 proteins and apoptosis in autosomal- dominant polycystic kidney disease. Kidney Int 2002;61:1220- 30. [CrossRef]
Agostini M, Tucci P, Melino G. Cell death pathology: pers- pective for human diseases. Biochem Biophys Res Commun 2011;414:451-5. [CrossRef]
Lorz C, Benito-Martin A, Justo P, Sanz AB, Sanchez-Ni-o MD, Santamaria B, et al. Modulation of renal tubular cell survi- val: where is the evidence? Curr Med Chem 2006;13:449-54. [CrossRef]
Sanchez-Ni-o MD, Benito-Martin A, Gonçalves S, Sanz AB, Ucero AC, Izquierdo MC, et al. TNF superfamily: a growing saga of kidney injury modulators. Mediators Inflamm 2010;2010. pii: 182958.
Sanchez-Ni-o MD, Benito-Martin A, Ortiz A. New para- digms in cell death in human diabetic nephropathy. Kidney Int 2010;78:737-44. [CrossRef]
Collison A, Foster PS, Mattes J. Emerging role of tumour nec- rosis factor-related apoptosis-inducing ligand (TRAIL) as a key regulator of inflammatory responses. Clin Exp Pharmacol Physiol 2009;36:1049-53. [CrossRef]
Di Bartolo BA, Cartland SP, Harith HH, Bobryshev YV, Schop- pet M, Kavurma MM. TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL. PLoS One 2013;8:e74211. [CrossRef]
Secchiero P, Gonelli A, Carnevale A, Milani D, Pandolfi A, Zella D, et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and Erk pathway. Circulation 2003;107:2250-6. [CrossRef]
Xiang G, Yue L, Zhang J, Xiang L, Dong J. The relationship between circulating TRAIL and endothelial dysfunction in subc- linical hypothyroidism. Endocrine 2015;49:184-90. [CrossRef]
de Almeida EAF, Alho I, Marques F, Thiran C, Bicho MP, Prata M. Haemoglobin and erythropoietin levels in polycystic kidney disease. Nephrol Dial Transplant 200;23:412-3.
Eckardt KU, Möllmann M, Neumann R, Brunkhorst R, Burger HU, Lonnemann G, et al. Erythropoietin in polycystic kidneys. J Clin Invest 1989;84:1160-6. [CrossRef]
Zauli G, Secchiero P. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev 2006;17:245-57. [CrossRef]
Choi JW. Relationships between tumor necrosis factor (TNF)- related apoptosis-inducing ligand (TRAIL) and hematopoietic ac- tivity in healthy adults. Ann Hematol 2005;84:728-33. [CrossRef]
Zamai L, Secchiero P, Pierpaoli S, Bassini A, Papa S, Alnem- ri ES, et al. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 2000;95:3716-24.
Silvestris F, Cafforio P, Tucci M, Dammacco F. Negative regu- lation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood 2002;99:1305-13.